Claims for Patent: 5,686,422

Summary for Patent: 5,686,422

Title:	Synthetic inhibitors of mammalian collagenase
Abstract:	The present invention relates to compounds of the formula: wherein Nal is L-3-(2-naphthyl)alanine; m is the integer 0 or 1; n is an integer from 0-2; AA.sub.1 is a non-polar hydrophobic aromatic amino acid; AA.sub.2 is alanine, glycine, leucine, isoleucine or phenylalanine; AA.sub.3 is one of the twenty naturally occurring amino acids, preferably glutamine or arginine; R.sub.1 is hydrogen, alkyl having from 1-10 carbon atoms, alkanoyl having from 2-10 carbon atoms, or aroyl having from 7-10 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is hydrogen, alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl, wherein aryl moieties have from 6-10 carbon atoms; X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3 ; and salts thereof.
Inventor(s):	Gray; Robert D. (Louisville, KY), Spatola; Arno F. (Louisville, KY), Miller; Robert B. (Vernon Hills, IL), Burns; Frank R. (Louisville, KY), Paterson; Christopher (Louisville, KY)
Assignee:	Research Corporation Technologies, Inc. (Tucson, AZ)
Application Number:	08/468,491
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound having the formula: or pharmaceutically acceptable salts thereof wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is alanine, glycine, phenylalanine or isoleucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having 2-10 carbon atoms, or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms; aryl or arylalkyl wherein the aryl moieties have from 6-10 ring carbon atoms; X is NH.sub.2, [OH,] OCH.sub.3 or OCH.sub.2 CH.sub.3, and a pharmaceutical carrier therefor. 2. The pharmaceutical composition according to claim 1 wherein R.sub.3 is an alkyl. 3. The pharmaceutical composition according to claim 2 wherein R.sub.3 is a branched alkyl. 4. The pharmaceutical composition according to claim 1 wherein R.sub.3 is alkyl having 4 carbon atoms. 5. The pharmaceutical composition according to claim 1 wherein R.sub.3 is isobutyl. 6. The pharmaceutical composition according to claim 1 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 7. The pharmaceutical composition according to claim 1 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 8. The pharmaceutical composition of claim 1 wherein m is 1 and AA.sub.2 is alanine. 9. The pharmaceutical composition according to claim 1 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3, m is 1 and AA.sub.2 is alanine. 10. The pharmaceutical composition according to claim 1 wherein the compound has the formula: 11. The pharmaceutical composition according to claim 1 wherein the compound has the formula: 12. 12. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound having the formula: wherein m is 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is leucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having from 2-10 carbon atoms or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl, wherein the aryl moieties have from 6-10 carbon atoms; and X is NH.sub.2, [OH,] OCH.sub.3 or OCH.sub.2 CH.sub.3 and a pharmaceutical carrier therefor. 13. The pharmaceutical composition according to claim 12 wherein R.sub.3 is alkyl. 14. The pharmaceutical composition according to claim 13 wherein R.sub.3 is a branched alkyl having 4 carbon atoms. 15. The pharmaceutical composition according to claim 12 wherein R.sub.3 is isobutyl. 16. The pharmaceutical composition according to claim 12 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 17. The pharmaceutical composition according to claim 12 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.' is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 18. The pharmaceutical composition according to claim 12 wherein the compound has the formula: 19. 19. A method of reducing the adverse effects of mammalian collagenase in a mammal which comprises administering to said mammal a pharmaceutically effective amount of a compound of the formula: or pharmaceutically acceptable salts thereof wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is alanine, glycine, phenylalanine or isoleucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having 2-10 carbon atoms, or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl wherein the aryl moieties have from 6-10 ring carbon atoms; X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3. 20. The method according to claim 19 wherein R.sub.3 is alkyl. 21. The method according to claim 20 wherein R.sub.3 is a branched alkyl. 22. The method according to claim 21 wherein R.sub.3 is alkyl having 4 carbon atoms. 23. The method according to claim 22 wherein R.sub.3 is isobutyl. 24. The method according to claim 19 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 25. The method according to claim 19 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 26. The method according to claim 19 wherein m is 1 and AA.sub.2 is alanine. 27. The method according to claim 19 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3, m is 1 and AA.sub.2 is alanine. 28. The method according to claim 19 wherein the compound has the formula: 29. The method according to claim 19 wherein the compound has the formula: 30. 30. The method of claim 19 wherein said disorder is rheumatoid arthritis. 31. The method of claim 19 wherein said disorder is periodontal disease. 32. The method of claim 19 wherein said disorder is tumor metastasis. 33. A method of reducing the adverse effects of mammalian collagenase in a mammal which comprises administering to said mammal a pharmaceutically effective amount of a compound of the formula: wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is leucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having from 2-10 carbon atoms or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl, wherein aryl moieties have from 6-10 carbon atoms; X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3. 34. The method according to claim 33 in which R.sub.3 is alkyl. 35. The method according to claim 33 wherein R.sub.3 is a branched alkyl having 4 carbon atoms. 36. The method according to claim 33 wherein R.sub.3 is isobutyl. 37. The method according to claim 33 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 38. The method according to claim 33 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 39. The method according to claim 33 wherein the compound is 40. 40. The method of claim 33 wherein said disorder is rheumatoid arthritis. 41. The method of claim 33 wherein said disorder is periodontal disease. 42. The method of claim 33 wherein said disorder is tumor metastasis. 43. A method for treating corneal ulceration in mammals comprising administering to a mammal in need of such treatment a corneal ulceration inhibiting effective amount of a compound having the formula: or pharmaceutically acceptable salts thereof wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is alanine, glycine, phenylalanine or isoleucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having 2-10 carbon atoms, or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms; aryl or arylalkyl wherein the aryl moieties having from 6-10 ring carbon atoms; X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3. 44. The method of claim 43 wherein said corneal ulceration is the result of alkali burning of the cornea. 45. The method of claim 43 wherein said corneal ulceration is the result of infectious keratitis. 46. The method of claim 45 wherein said infectious keratosis is induced by infection by Pseudomonas aeruginosa. 47. A method for treating corneal ulceration in mammals comprising administering to a mammal having corneal ulceration a corneal ulceration inhibiting effective amount of a compound having the formula: wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine, or .epsilon.-amino blocked lysine; AA.sub.2 is leucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having from 2-10 carbon atoms or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl, wherein aryl moieties have from 6-10 carbon atoms; X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3. 48. The method of claim 47 wherein said corneal ulceration is the result of alkali burning of the cornea. 49. The method of claim 47 wherein said corneal ulceration is the result of infectious keratitis. 50. The method of claim 49 wherein said infectious keratosis is induced by infection by Pseudomonas aeruginosa. 51. The method according to claim 43 wherein R.sub.3 is alkyl having 4 carbon atoms. 52. The method according to claim 43 wherein R.sub.3 is branched alkyl. 53. The method according to claim 43 wherein R.sub.3 is isobutyl. 54. The method according to claim 43 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 55. The method according to claim 43 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 56. The method according to claim 43 wherein m is 1 and AA.sub.2 is alanine. 57. The method according to claim 43 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3, m is 1 and AA.sub.2 is alanine. 58. The method according to claim 43 wherein the compound has the formula: 59. The method according to claim 43 wherein the compound is 60. The method according to claim 47 wherein R.sub.3 is a branched alkyl having 4 carbon atoms. 61. The method according to claim 47 wherein R.sub.3 is isobutyl. 62. The method according to claim 47 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 63. The method according to claim 47 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 64. The method according to claim 47 wherein the compound has the formula: 65. A compound of the formula: or pharmaceutically acceptable salts thereof wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan, tyrosine or .epsilon.-amino blocked lysine AA.sub.2 is alanine, glycine, Phenylalanine or isoleucine, R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having 2-10 carbon atoms, or aroyl having from 7-11 carbon atoms, R.sub.2 is hydrogen or alkyl having 1-6 carbon atoms, R.sub.3 is alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl wherein the aryl moieties have from 6-10 ring carbon atoms; and X is NH.sub.2, [OH,] OCH.sub.3 or OCH.sub.2 CH.sub.3. 66. The compound according to claim 65 wherein R.sub.3 is alkyl. 67. The compound according to claim 65 wherein R.sub.3 is a branched alkyl. 68. The compound according to claim 65 wherein R.sub.3 is alkyl having 4 carbon atoms. 69. The compound according to claim 65 wherein R.sub.3 is isobutyl. 70. The compound according to claim 65 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 71. The compound according to claim 65 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.5. 72. The compound according to claim 65 wherein m is 1 and AA.sub.2 is alanine. 73. The compound according to claim 65 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3, m is 1 and AA.sub.2 is alanine. 74. The compound according to claim 65 wherein the compound has the formula: 75. The compound according to claim 65 wherein the compound is 76. A compound having the formula: ##STR7## wherein m is an integer 0 or 1; AA.sub.1 is phenylalanine, naphthylalanine, tryptophan tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is leucine; R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having from 2-10 carbon atoms or aroyl having from 7-11 carbon atoms; R.sub.2 is hydrogen or alkyl having from 1-6 carbon atoms; R.sub.3 is alkyl having 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl, wherein aryl moieties have from 6-10 carbon atoms; X is NH.sub.2, OCH.sub.3 or OCH.sub.2 CH.sub.3 . 77. The compound according to claim 76 in which R.sub.3 is alkyl. 78. The compound according to claim 76 wherein R.sub.3 is a branched alkyl having 4 carbon atoms. 79. The compound according to claim 76 wherein R.sub.3 is isobutyl. 80. The compound according to claim 76 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 81. The compound according to claim 76 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.3. 82. The compound according to claim 76 having the formula: 83. 83. A compound of the formula: wherein AA.sub.1 is phenylalanine, naphthylalanine, tryptophan tyrosine or .epsilon.-amino blocked lysine; AA.sub.2 is alanine, glycine, phenylalanine, leucine or isoleucine, AA.sub.3 is glutamine or arginine, m is an integer 0 or 1, n is an integer 1 or 2, R.sub.1 is hydrogen, alkyl having 1-10 carbon atoms, alkanoyl having 2-10 carbon atoms, or aroyl having from 7-11 carbon atoms, R.sub.2 is hydrogen or alkyl having 1-6 carbon atoms, R.sub.3 is alkyl having from 2-10 carbon atoms, cycloalkyl having from 3-6 carbon atoms, aryl or arylalkyl wherein the aryl moieties have from 6-10 ring carbon atoms, and X is NH.sub.2, OH, OCH.sub.3 or OCH.sub.2 CH.sub.3. 84. The compound according to claim 83 wherein R.sub.3 is alkyl. 85. The compound according to claim 83 wherein R.sub.3 is branched alkyl. 86. The compound according to claim 83 wherein R.sub.3 is alkyl having 4 carbon atoms. 87. The compound according to claim 83 wherein R.sub.3 is isobutyl. 88. The compound according to claim 83 wherein R.sub.3 is isobutyl and R.sub.2 is hydrogen. 89. The compound according to claim 83 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.2 CH.sub.2. 90. The compound according to claim 83 wherein m is 1 and AA.sub.2 is alanine. 91. The compound according to claim 83 wherein R.sub.2 is hydrogen or CH.sub.3, R.sub.3 is isobutyl, R.sub.1 is hydrogen and X is NH.sub.2 or OCH.sub.3 OCH.sub.2 CH.sub.3, m is 1 and AA.sub.2 is alanine. 92. The compound of claim 83 wherein n is 1 and AA.sub.3 is glutamine or arginine. 93. The compound of claim 83 wherein the compound has the formula: 94. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claim 83 and a pharmaceutical carrier therefor. 95. A method of inhibiting the degradation of collagen in mammals by mammalian collagenase comprising administering to said mammal an inhibiting effective amount of a compound according to claim 83. 96. A method for treating corneal ulceration in mammals comprising administering to said mammal a corneal ulceration inhibiting effective amount of a compound according to claim 83.

Details for Patent 5,686,422

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-11-11